EcoDrugPlus

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSDLEG00000006151
Gene Symbol: ABL1
3 Cross references
204 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSDLEG00000004858
Gene Symbol: ADAM17
3 Cross references
283 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSDLEG00000008340
Gene Symbol: ADAMTS5
3 Cross references
199 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSDLEG00000000134
Gene Symbol: AKT1
3 Cross references
220 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSDLEG00000013262
Gene Symbol: AKT2
3 Cross references
257 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSDLEG00000012542
Gene Symbol: AKT3
1 Cross references
201 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSDLEG00000020332
Gene Symbol: ALK
1 Cross references
195 Possible Orthologues:

Atp Binding Cassette Subfamily B Member 1

Ensembl ID : ENSDLEG00000016643
Gene Symbol: ABCB1
3 Cross references
161 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSDLEG00000006588
Gene Symbol: ABCC1
1 Cross references
203 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSDLEG00000016659
Gene Symbol: ABCC8
1 Cross references
245 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSDLEG00000002785
Gene Symbol: ABCC9
3 Cross references
232 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSDLEG00000002880
Gene Symbol: ATP4A
3 Cross references
183 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).